SOLO-2 GINECO-OV227/ENGOT-OV21 Study of OLaparib in Ovarian Cancer - - PowerPoint PPT Presentation

▶

Oct 27, 2022 365 likes •406 views

Closed Trial status update SOLO-2 GINECO-OV227/ENGOT-OV21 Study of OLaparib in Ovarian Cancer Trial setting: Platinum Sensitive Relapsed High grade serous ovarian cancer with a BRCA mutation or high grade endometrioid cancer Study Design: A

SLIDE 1

SOLO-2

GINECO-OV227/ENGOT-OV21

Trial setting: Platinum Sensitive Relapsed High grade serous ovarian cancer with a BRCA mutation or high grade endometrioid cancer Study Design: A Phase III, Randomised, Double Blind, Placebo Controlled Sponsor(s): AstraZeneca Final No. of patients: 295 Timeline (first patient – trial closing): Aug 2013- Aug 2021 Publications: In submission Planned publications and substudies: To be discused at the SOLO-2 TSC meeting (June 3rd 6:30 am) Closed Trial – status update

SOLO-2 - GCIG June 1st 2017

Study of OLaparib in Ovarian Cancer

SLIDE 2

Primary Endpoint presented at SGO

n March 2017

SOLO-2 - GCIG June 1st 2017

SLIDE 3

Tomorrow, do not miss ….

M. Friedlander Oral presentation on QOL data
Poster discussion on Tolerability

SOLO-2 - GCIG June 1st 2017